ROVIELLO, GIANDOMENICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.031
EU - Europa 6.196
AS - Asia 1.684
AF - Africa 39
SA - Sud America 12
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 17.971
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.012
RU - Federazione Russa 2.942
IT - Italia 935
PL - Polonia 835
IE - Irlanda 735
SG - Singapore 496
CN - Cina 464
HK - Hong Kong 387
SE - Svezia 300
IN - India 153
JO - Giordania 85
DE - Germania 72
FI - Finlandia 61
ES - Italia 60
GB - Regno Unito 60
CH - Svizzera 58
VN - Vietnam 48
FR - Francia 36
CI - Costa d'Avorio 34
TR - Turchia 31
AT - Austria 29
CA - Canada 19
LU - Lussemburgo 17
NL - Olanda 14
UA - Ucraina 14
BR - Brasile 11
JP - Giappone 11
BE - Belgio 10
AU - Australia 8
PT - Portogallo 6
NO - Norvegia 4
CZ - Repubblica Ceca 3
DZ - Algeria 2
IL - Israele 2
KR - Corea 2
RS - Serbia 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
BY - Bielorussia 1
EC - Ecuador 1
EU - Europa 1
HR - Croazia 1
ID - Indonesia 1
LI - Liechtenstein 1
MU - Mauritius 1
MY - Malesia 1
TH - Thailandia 1
TW - Taiwan 1
Totale 17.971
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.894
Fairfield 1.595
Warsaw 830
Ashburn 781
Woodbridge 734
Dublin 732
Seattle 675
Houston 574
Cambridge 564
Wilmington 521
Singapore 397
Lawrence 334
Altamura 332
Moscow 225
Beijing 210
Ann Arbor 203
Chandler 199
Hong Kong 188
Princeton 171
Boston 156
Florence 112
Mumbai 108
San Diego 79
Shanghai 78
Barcelona 57
Bern 57
Helsinki 52
Buffalo 48
Dong Ket 46
Bremen 41
Milan 41
Medford 39
Norwalk 37
Abidjan 34
Rome 33
West Jordan 31
Falls Church 29
Vienna 29
Boardman 27
New York 27
Yubileyny 25
Pune 23
Kent 22
Arezzo 20
London 19
Hillsboro 16
Adana 14
Los Angeles 14
Toronto 14
Roodt-sur-Syre 12
Siena 11
Brescia 10
Paris 10
Brussels 9
Guangzhou 9
Padova 9
Redmond 9
Washington 9
Wuhan 9
Andover 8
Lappeenranta 8
Decatur 7
New Bedfont 7
Romola 7
São Paulo 7
Xuzhou 7
Marietta 6
Palermo 6
Prato 6
Sydney 6
Venice 6
Chennai 5
Dearborn 5
Lisbon 5
Phoenix 5
Prescot 5
San Giovanni Valdarno 5
Shenzhen 5
Turin 5
Amandola 4
Bologna 4
Castelliri 4
Fontebuona 4
Gaziantep 4
Grottammare 4
Ladispoli 4
Laurel 4
Munich 4
Naples 4
Oslo 4
Parma 4
Pisa 4
Rui'an 4
Tokat Province 4
Trevignano 4
Wandsworth 4
Acton 3
Alba 3
Castiglione del Lago 3
Chicago 3
Totale 12.785
Salva come PNG Salva come JPEG
Nome #
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience 220
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 151
Isolated Testicular Metastasis from Prostate Cancer 141
Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? 134
Is there still a place for docetaxel rechallenge in prostate cancer? 131
Adjuvant treatment for EGFR-mutated non-small cell lung cancer: Do we have a major breakthrough? 126
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer 122
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer 119
Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer 119
Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer? 119
An exceptional overall survival using bevacizumab beyond progression in a patient with Non-small cell lung cancer 118
Cabozantinib in advanced non-clear-cell renal cell carcinoma: is it the way clearer now? 116
Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223 114
A husband and a wife with simultaneous presentation of glioblastoma multiforme: a case report 112
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer 110
Prognostic role of T3/T4 ratio in metastatic renal cell carcinoma (mRCC): Preliminary results of the threeFOUR multicenter study (Meet-Uro 14) 110
Bevacizumab in small cell lung cancer 109
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience 109
Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights 106
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 106
The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015 105
Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma 105
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers 104
Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer 103
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study 103
Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033 102
Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer 102
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer 101
A Phase II study of olaparib in breast cancer patients: Biological evaluation from a 'window of opportunity' trial 101
Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study 101
Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer 100
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials 99
Angiogenesis inhibitors in gastric and gastroesophageal junction cancer 99
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate 99
Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status 99
Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials 97
Role of ATP-binding cassette transporters in cancer initiation and progression 97
Immunotherapy-based combinations versus standard first-line and hypothyroidism risk 97
Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer 97
Surgical management of advanced gastric cancer: An evolving issue 97
Ntrk gene fusion detection in atypical spitz tumors 96
Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis 94
The distinctive nature of adenocarcinoma of the lung 94
Acute Massive and Submassive Pulmonary Embolism: Preliminary Validation of Aspiration Mechanical Thrombectomy in Patients with Contraindications to Thrombolysis 94
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review 93
Advances in systemic therapy for metastatic breast cancer: future perspectives 93
Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer 92
28. Role of neoadjuvant chemotherapy with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for treatment of primary ovarian cancer with peritoneal carcinomatosis 91
A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical development 91
Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis 91
Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience 91
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience 91
Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035: Corticosteroid-associated Adverse Events in Elderly Patients 90
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 90
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival 90
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy 89
Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis 89
The Role of Microsatellite Instability in Positive Margin Gastric Cancer Patients 89
A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin 89
Advances in systemic therapy for malignant mesothelioma: future perspectives 88
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 88
Familial aggregation of gastric cancer with microsatellite instability** 87
Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status 87
Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis 87
New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials 87
Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma 86
C-Met targeting in advanced gastric cancer: An open challenge 86
Neoadjuvant chemotherapy and radical radiotherapy associated with cetuximab for laryngeal cancer in a pancreas and renal recipient 86
Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: A literature-based meta-analysis of randomized trials 86
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials 86
No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials 85
Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis 84
Molecular key to understand the gastric cancer biology in elderly patients—The role of microsatellite instability 84
High-risk and low-risk gastric cancer areas in Italy and its association with microsatellite instability 84
Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer 83
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials 83
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 83
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment 83
In reply to Egger et al.: Lack of benefit from adjuvant postoperative radiotherapy and issues raised about upfront management of high- and very-high-risk prostate cancer patients 83
New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When 83
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer 82
Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives 82
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer 82
Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand? 82
Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience 82
Evolution and emerging future of cytoreducxtive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: From treating the incurable to preventing recurrence 82
KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status 81
Is the Gleason score the driver for the treatment decision-making of patients with castration-resistant prostate cancer in the new era of the anti-androgenic therapies? 81
Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy? 81
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer 81
An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC) 81
Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials 81
Radiotherapy after prostatectomy in high‑risk prostate cancer 81
Inflammation in Urological Malignancies: The Silent Killer 80
Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas 80
Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma 80
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene 80
Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-cardia Gastric Cancer 79
PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients 78
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab 77
Totale 9.639
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.280
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.280
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.397 0 0 0 0 625 541 480 491 485 303 350 122
2020/20212.191 225 219 30 474 131 122 98 73 313 164 222 120
2021/20221.018 9 11 96 29 29 107 11 137 87 38 107 357
2022/20232.731 269 770 69 162 36 447 491 110 179 51 53 94
2023/20241.640 49 90 273 79 102 164 57 299 62 219 117 129
2024/20256.451 482 1.279 695 1.638 2.357 0 0 0 0 0 0 0
Totale 18.369